Actualités > Our articles
Retour
Biodol Therapeutics, an innovative French start-up founded by Didier Rognan, Research Director at the CNRS, Director of the Laboratoire d’Innovation Thérapeutique and member of Strasbourg’s Institut du Médicament, has successfully raised €7 million to advance its next-generation pain therapy into clinical trials.
Specializing in the development of cutting-edge pain relief treatments, the company was selected for funding by BPI France as part of the i-DEMO call for projects. In parallel, the venture capital fund V-Bio Ventures, which transforms scientific innovation into real products with a positive impact on our lives, also lent its support, enabling Biodol to team up with two brilliant academic partners: the Montpellier Neuroscience Institute and the Strasbourg Therapeutic Innovation Laboratory.
The total funding of 7 million euros will be dedicated to the development of an innovative program of small molecule negative allosteric modulators (NAMs) targeting the FLT3 receptor. This will enable the first human clinical trials to be launched with BDT272, a promising compound which has demonstrated excellent safety and efficacy in preclinical tests.
The FLT3 receptor plays a crucial role in pain mechanisms. Its specificity has been highlighted in several international scientific publications, underscoring its potential. This promising innovation meets high medical needs and could transform the scientific landscape.
Biodol Therapeutics is a French academic company, backed by a portfolio of patents held by several renowned research institutes, including the Universities of Montpellier and Strasbourg, INSERM and CNRS. The program has been approved by scientific clusters such as Eurobiomed and Biovalley, and is perfectly aligned with the priorities of the France 2030 plan for the development of innovative companies.